141 related articles for article (PubMed ID: 24490439)
1. [Subcutaneous Rituximab is effective and safe].
Häckel A
Med Monatsschr Pharm; 2014 Jan; 37(1):39-40. PubMed ID: 24490439
[No Abstract] [Full Text] [Related]
2. [Subcutaneous administration of MabThera for therapy of non-Hodgkin lymphomas frees patients and medical personnel].
Pflege Z; 2013 Apr; 66(4):253. PubMed ID: 23634557
[No Abstract] [Full Text] [Related]
3. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
[TBL] [Abstract][Full Text] [Related]
4. Rituximab in the treatment of non-Hodgkin's lymphoma--a critical evaluation of randomized controlled trials.
Griffin MM; Morley N
Expert Opin Biol Ther; 2013 May; 13(5):803-11. PubMed ID: 23560506
[TBL] [Abstract][Full Text] [Related]
5. Rituximab faster infusion for patients with non-Hodgkin's lymphoma in the United States: implications for nursing practice.
Dawson K
J Infus Nurs; 2013; 36(3):172-8. PubMed ID: 23558916
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular adverse events complicating the administration of rituximab: report of two cases.
Passalia C; Minetto P; Arboscello E; Balleari E; Bellodi A; Del Corso L; Molinari E; Ponassi I; Oneto C; Sicbaldi V; Ghio R
Tumori; 2013; 99(6):288e-92e. PubMed ID: 24503806
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for rituximab-induced interstitial lung diseases in patients with malignant lymphoma.
Cha SI; Choi KJ; Shin KM; Lim J; Yoo SS; Lee J; Lee SY; Kim CH; Park JY
Respiration; 2013; 85(2):175. PubMed ID: 23234874
[No Abstract] [Full Text] [Related]
8. Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: a multicenter phase II study.
Tobinai K; Igarashi T; Itoh K; Kurosawa M; Nagai H; Hiraoka A; Kinoshita T; Uike N; Ogura M; Nawano S; Mori S; Ohashi Y;
Cancer Sci; 2011 Sep; 102(9):1698-705. PubMed ID: 21645173
[TBL] [Abstract][Full Text] [Related]
9. No studies have shown improved overall survival with maintenance therapy.
Ujjani C
Clin Adv Hematol Oncol; 2014 Aug; 12(8):541, 544-6. PubMed ID: 25356580
[No Abstract] [Full Text] [Related]
10. Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy.
Pei SN; Ma MC; Wang MC; Kuo CY; Rau KM; Su CY; Chen CH
Ann Hematol; 2012 Jul; 91(7):1007-12. PubMed ID: 22273839
[TBL] [Abstract][Full Text] [Related]
11. Rituximab by subcutaneous route.
Solal-Celigny P
Expert Rev Hematol; 2015 Apr; 8(2):147-53. PubMed ID: 25749209
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom.
Rule S; Collins GP; Samanta K
J Med Econ; 2014 Jul; 17(7):459-68. PubMed ID: 24720836
[TBL] [Abstract][Full Text] [Related]
13. Rituximab Faster Infusion for Patients With Non-Hodgkin's Lymphoma in the United States: Implications for Nursing Practice.
Dawson K
J Infus Nurs; 2015; 38 Suppl 6():S4-S10. PubMed ID: 26536411
[TBL] [Abstract][Full Text] [Related]
14. Maintenance rituximab every 2 months is more toxic than every 3 months in patients with non-Hodgkin lymphoma.
Rashidi A; Oak E; Bartlett NL
Blood; 2015 May; 125(21):3354-5. PubMed ID: 25999445
[No Abstract] [Full Text] [Related]
15. Rituximab-related urticarial reaction overlying primary cutaneous follicle centre lymphoma: histological appearance and pathophysiological hypotheses.
Ingen-Housz-Oro S; Ortonne N; Chosidow O
J Eur Acad Dermatol Venereol; 2014 Jul; 28(7):976-8. PubMed ID: 24206369
[No Abstract] [Full Text] [Related]
16. Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma.
Nagai H; Ogura M; Kusumoto S; Takahashi N; Yamaguchi M; Takayama N; Kinoshita T; Motoji T; Ohyashiki K; Kosugi H; Matsuda S; Ohnishi K; Omachi K; Hotta T
Eur J Haematol; 2011 Feb; 86(2):117-23. PubMed ID: 21070370
[TBL] [Abstract][Full Text] [Related]
17. [Fulminant hepatitis B as a result of reactivation in hematologic patient after chemotherapy combined with rituximab].
Cantudo-Muñoz P; Anguita-Arance MM; Muñoz-Peña C; Amores-Antequera C
Rev Esp Quimioter; 2015 Feb; 28(1):56-7. PubMed ID: 25690147
[No Abstract] [Full Text] [Related]
18. Hepatitis B reactivation in patient with non-Hodgkin's lymphoma receiving rituximab-based chemotherapy: need for education and attention.
Yang JD; Girotra M; Vaid A; Duarte-Rojo A
J Ark Med Soc; 2013 Nov; 110(6):110-2. PubMed ID: 24367885
[TBL] [Abstract][Full Text] [Related]
19. Four cases of rituximab-associated melanoma.
Velter C; Pagès C; Schneider P; Osio A; Brice P; Lebbé C
Melanoma Res; 2014 Aug; 24(4):401-3. PubMed ID: 24743053
[TBL] [Abstract][Full Text] [Related]
20. [Generalized lymphadenopathy and B symptoms].
Nägelein R
Internist (Berl); 2006 Sep; 47(9):974; author reply 974. PubMed ID: 17245841
[No Abstract] [Full Text] [Related]
[Next] [New Search]
